Tuesday, May 14, 2024
HomeTagsSymptomatic Obstructive

Symptomatic Obstructive

Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial

Bristol Myers Squibb announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class cardiac myosin inhibitor, significantly...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics